Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUM-101 Malaria Vaccine in Adults Residing in Malaria-endemic Settings
NCT07124156Phase 1Withdrawn
- Sponsor
- European Vaccine Initiative
- Start
- Mar 2026
- Primary completion
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, double-blind trial of SUM-101 in malaria (2 arms), sponsored by European Vaccine Initiative. Primary endpoints: Efficacy - Time to diagnosis, Frequency of local and systemic solicited adverse events and 4 more. Planned start Mar 2026; status: withdrawn.
02
Drugs
SUM-101
03
Conditions
malaria
Beyond the preview
Go deeper on NCT07124156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07124156.